@lfbpharmd

Pharmacist and Researcher

Joined June 2019
  • Tweets25
  • Following323
  • Followers106
Leo Buckley retweeted
Zaid Jilani
@ZaidJilani
12 Nov 2025
Why is Trump simultaneously murdering people on small boats whose identities we don’t really know (but he insists they’re drug smugglers) while also freeing people we *know* are guilty of drug crimes?
New York Post
@nypost
11 Nov 2025
LI drug dealer freed by Trump now convicted of molesting his kids’ nanny and assaulting toddler trib.al/riuDIE8
273
10,666
106
61,856
1,318,406
REDHART2 is a simple study - hospitalized for HFrEF --> CPET within 2 weeks of discharge, treatment with anakinra (or placebo, 2:1) for 6 months, CPET repeated at 6, 12, and 24 weeks. Four visits in 6 months all at VCU. Reach out to me or @bvantassell with questions.
AntonioAbbate
@AbbateAntonio
8 Jan 2023
Interleukin-1 in recently decompensated heart failure- REDHART2 study- in the last phase of enrollment @VCUHealthHeart @VCUHealth clinicaltrials.gov/ct2/show/… -Reach out with referrals/questions. @bvantassell @VCUPharmacy @VCUDPOSChair @CardioUva @UVACVRC
6
5
2,156
Interleukin-1 in recently decompensated heart failure- REDHART2 study- in the last phase of enrollment @VCUHealthHeart @VCUHealth clinicaltrials.gov/ct2/show/… -Reach out with referrals/questions. @bvantassell @VCUPharmacy @VCUDPOSChair @CardioUva @UVACVRC
6
1
17
3,768
Antonio Abbate, MD & Ben Van Tassell, PharmD - Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) (VCU-ART3) @AbbateAntonio @bvantassell #VCUART3Trial #MyocardialInfarction #Cardiology #Research cardiologytalk.com/video/634…
4
7
Journal publication is a multi-billion industry… and this article estimates that academics donate at least $1.5b annually in labor to support the current enterprise. Write papers, donate reviews, often pay for publication. What a model. researchintegrityjournal.bio… HT @atulbutte
7
78
14
193
We received feedback on our latest set of faculty surveys but don’t believe it is representative of the faculty because of what we have been told in private meetings. Thanks for participating!
5
56
9
549
Are the NLRP3 inflammasome and interleukin 1-beta potentially novel therapeutic targets for the treatment of #pericarditis? Find out in this new issue of #JACCBTS: bit.ly/3pGKglm #CardioImmunology
Mauro, A.G. et al. J Am Coll Cardiol Basic Trans Science. 2021;6(2):137-50

ALT Mauro, A.G. et al. J Am Coll Cardiol Basic Trans Science. 2021;6(2):137-50

7
2
22
Solid team work @VCUHealthHeart - ask me how to join this research team
Juan Chiabrando@jgchiabrando1
11 Feb 2021
Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure
2
3
STAT request: 2021 MeRIT Scholarship Applications due today February 8 at 8pm EST. Receive $3,000 to develop expertise in investigator-initiated research over a 2-year program. Contact [email protected] (@lfbpharmd ) for questions
2
3
The novel program led by pharmacists is a model for remote healthcare delivery to reduce inequities and improve QOC. ms.spr.ly/6012pyHqj #AHA20

Remote, Non-Physician-Led Care Cuts LDL, BP in High-Risk Patients

The program provides a model to expand remote healthcare delivery, reduce healthcare inequities, and improve quality of care, observers say.

medscape.com
1
2
Proud to have been part of RHAPSODY at @VCUHealthHeart @VCU_CCTR Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis | NEJM nejm.org/doi/full/10.1056/NE…

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis | NEJM

Interleukin-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine trap, were studied previously in a ph...

nejm.org
Massimo Imazio@ImazioMassimo
17 Nov 2020
RHAPSODY trial results just released: Great presentation at AHA2020 by Allan Klein! Full paper on the NEJM. November 16, 2020 DOI: 10.1056/NEJMoa2027892 @AllanLKleinMD1
2
4
1
20
Thank so much @DLKirkman @vcukhs @kim_youngdeok #AHA20
This Post is from an account that no longer exists. Learn more
2
1
5
This month we kickoff with a new section “Emerging Concepts in Pharmacotherapeutics”, edited by @DaveDixonPharmD   #pharmacology #cardiovascular #clinical #bempedoic #hyperlipidemia #drugs #prescriptions
5
2
23
After sitting in study section last week reviewing proposals for K-series career development awards, thought I'd list my top 5 reasons why such proposals fail. (Not linked to any one submission.) Junior scientists who might be interested in applying - avoid these pitfalls!!
13
160
43
455
Remote, algorithm-driven, navigator-administered medication optimization enhanced utilization and dose titration of neurohormonal antagonists versus usual care in HFrEF. This approach may represent a novel strategy to address underutilization of GDMT ja.ma/3c88GPI
2
4
Medicaid Expansion & Antihyperglycemic Therapies in @ADA_Journals by @adsumarsono, @sara_rm84, & colleagues. Low-income adults carry a disproportionate burden of CV disease. Improving insurance coverage represents a key determinant of therapeutic access. care.diabetesjournals.org/co…
18
3
50
I am excited to share our editorial just published on @JACCJournals where we discuss the role of nutrition in the management of heart failure, beyond dietary sodium restriction. @vcukhs @VCUCHS @VCUnews heartfailure.onlinejacc.org/…
6
9
1
27
COPS trial: in a small RCT, colchicine did not improve a composite of death or CV outcomes at 12 mos post ACS. Small # of events. Adverse non-CV mortality signal (5 vs 0 favoring placebo) 🤷🏽‍♂️ @UTSWIMchief @UTSWCardfellow ahajournals.org/doi/pdf/10.1…
1
1
VCUART3 study showed promising benefits of IL-1 blockade with anakinra in STEMI. ahajournals.org/doi/10.1161/… Looking for other centers in the USA for a phase II trial with a novel IL-1 blocker (contact me [email protected] if interested)
2
19
2
38
Nice summary and overview of cytokines in COVID-19 -- thanks to Leo Buckley, PharmD @lfbpharmd for leading this effort. bit.ly/3iB78zp
1
2
1
12
Load more